See You Next Year! 📅
Upcoming Webinars – Watch for Announcements⏰ 11:00 AM – 12:00 PM ET
You can watch previous sessions
hereFree Educational Credits Available.
This series is intended as a forum to share multidisciplinary experiences in cancer genetics around the world to better understand cancer variant detection methods, genomic interpretation, and cancer patient management.
📅 January 28, 2025 (Available OnDemand)
Title: Cases in Precision Oncology: Highlights from the 2024 ClinGen Somatic Cancer and VICC Virtual Molecular Tumor Board Case Series
📅 February 25, 2025 (Available OnDemand)
Title: Chromosomal Mimicry in Hematologic Malignancies
📅 March 25, 2025 (Available OnDemand)
Title: Complementary Use of Circulating Tumor Cell Sequencing and Tumor Sequencing
📅 May 27, 2025 (Available OnDemand)
Title:
Longitudinal Analysis in a Case of Langerhans Cell Histiocytosis 📅 June 24, 2025 (Available OnDemand)
Title:
Cases in Precision Oncology: Complex In-frame DELINS in Cancer 📅 August 26, 2025 (Available OnDemand)
Title:
Knowledgebase Resources Aiding the Assessment of the Clinical Impact of Somatic Variants Found in Cancer: In-Depth Looks at CIViC and OncoKB 📅 September 23, 2025 (Available OnDemand)
Title:
Overcoming Cytogenetic Diagnostic Challenges in Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Fusions 📅 October 28, 2025 (Available OnDemand)
Title:
An Algorithmic Panel-Based Approach to Molecular Diagnostics in Sinonasal Tumors
Accredited Continuing Education Information
Accredited Continuing Education Information:
AMA PRA Category 1 CreditsTM & CME Other
Accreditation
The American College of Medical Genetics and Genomics is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
The American College of Medical Genetics and Genomics designates this live activity for a maximum of 8.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Claiming your Educational Credits
Complete the activity and carefully complete the evaluation form. The deadline to claim educational credits is within 30 days from the date of the activity. Educational credit requests after this date will not be accepted.
Learner Data Consent
ACMG Education reports learner data to respective agency boards and you will be asked for consent during the evaluation process. Your compliance with deadlines and completing evaluations are part of the process in meeting learner needs and ACMG’s education mission.
Technical Support:
You can reach us by email at education@acmg.net or call 301-718-9603.
Support Center Hours: Monday – Friday, 9:00 AM – 5:00 PM Eastern Time.
Accredited Continuing Education Financial Disclosure
The American College of Medical Genetics and Genomics (ACMG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Accredited Continuing Education (ACE) for physicians. ACMG is an organization committed to improvement of patient care and general health by the incorporation of genetics and genomics into clinical practice.
ACMG has implemented the following procedures to ensure the independence of ACE activities from commercial influence/promotional bias, the Accreditation Council for Continuing Medical Education (ACCME) requires that providers (ACMG) must be able to demonstrate that: 1) everyone in a position to control the content of an ACE activity has disclosed all financial relationships that they have had in the past 24 months with ineligible* companies; 2) ACMG has implemented a mechanism to mitigate relevant financial relationships; and 3) all relevant financial relationships with ineligible companies are disclosed to the learners before the beginning of the educational activity. The learners must also be informed if no relevant financial relationships exist.
*Ineligible companies are defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
ACMG Education Policies
Please review the policies below regarding the ACMG Education program
All of the relevant financial relationships listed for these individuals have been mitigated.
|
NAME
|
ROLE
|
SESSION DATE
|
RELATIONSHIP/ COMPANY
|
|
|
Planning Member
|
Presenter Panelist Moderator
|
Peer Reviewer
|
|
|
|
Manuela Benary, PhD
|
●
|
●
|
|
All
|
Speaker: Novartis
|
|
Beth Pitel, MS
|
●
|
●
|
|
All
|
Somatic Advisory Board: Qiagen
|
|
Gordana Raca, MD, PhD, FACMG
|
●
|
●
|
●
|
All
|
Nothing to Disclose
|
|
Jason Saliba, PhD
|
●
|
●
|
|
All
|
Nothing to Disclose
|
|
Adrian Dubuc, PhD, FACMG
|
|
●
|
|
February 25
|
Nothing to Disclose
|
|
Amir Fathi, MD
|
|
●
|
|
February 25
|
Consultant: AbbVie, Amgen, Astellas Pharma, AstraZeneca,
Autolus, Bristol-Myers Squibb, Daiichi Sankyo Co, Genentech, Gilead Sciences Inc.,
Ipsen Biopharmaceuticals, Inc., Kite Pharma. Inc. Kura Oncology, Menarini Group,
Novartis, Orum, Pfizer, Prelude Therapeutics, Remix, Rigel Pharmaceuticals, Inc.,
Schrodinger, Servier Pharmaceuticals LLC, Syndax, Takeda Oncology
Grant: Abbvie, Servier Pharmaceuticals LLC
|
|
Gabriela Hobbs, MD
|
|
●
|
|
February 25
|
Consultant: Abbvie. Bristol Myers Squibb, GlaxoSmithKline,
Novartis, PharmaEssentia, Sobi Research: Incyte Corporation
|
|
Nisha Kanwar
|
|
●
|
|
March 25
|
Nothing to Disclose
|
|
Valentina Nardi, MD
|
|
●
|
|
February 25
|
Nothing to Disclose
|
|
Scott Ryall, PhD
|
|
●
|
|
February 25
|
Nothing to Disclose
|
|
Melissa Zhao, MD
|
|
●
|
|
February 25
|
Nothing to Disclose
|
|
Damian Rieke, MD
|
|
●
|
|
May 27
|
Consultant: Bayer; BeiGene, Ltd.; Eli Lilly and Company;
Johnson and Johnson; Servier Pharmaceuticals
|
|
Markus Möbs, PhD
|
|
●
|
|
May 27
|
Nothing to Disclose
|
|
Kaitlin Paxton
|
|
●
|
|
Jume 24
|
Nothing to Disclose
|
|
Kandelaria (Ande) Rumilla, MD
|
|
●
|
|
Jume 24
|
Nothing to Disclose
|
|
Malachi Griffith, PhD
|
|
●
|
|
August 26
|
Nothing to Disclose
|
|
Debyani Chakravarty, PhD
|
|
●
|
|
August 26
|
Nothing to Disclose
|
|
Nathan Kopp, Ph.D., FACMG
|
|
●
|
|
September 23
|
Nothing to Disclose
|
|
Ehab Atallah, MD
|
|
●
|
|
September 23
|
Consultant: AbbVie, Actinium Pharmaceuticals, Blueprint Medicines, Bristol Myers Squibb, Novartis, Syndax, Takeda Oncology
|
|
Karen-Sue Carlson, MD, PhD
|
|
●
|
|
September 23
|
Nothing to Disclose
|
|
Daniel Schlepphorst, DO
|
|
●
|
|
September 23
|
Nothing to Disclose
|
|
Maria Hintzke, MD
|
|
●
|
|
September 23
|
Nothing to Disclose
|
|
Eric Darrah, MD, PhD
|
|
●
|
|
September 23
|
Nothing to Disclose
|
|
Aaron Pollett, MD, FRCPC
|
|
●
|
|
October 28
|
Nothing to Disclose
|
|
Elan Hahn, MD, FRCPD
|
|
●
|
|
October 28
|
Consultancy ended: Merck
|
|
Enrique Sanz Garcia, MD, PhD
|
|
●
|
|
October 28
|
Grant: GlaxoSmithKline, Rgnta Therapeutics
|
|
Ezra Hahn, MD, FRCPC
|
|
●
|
|
October 28
|
Nothing to Disclose
|
|
Jane Radford, MHA, CHCP
|
●
|
|
|
All
|
Nothing to Disclose
|
|
Claudia Barnett
|
●
|
|
|
All
|
Nothing to Disclose
|
Disclaimer
ACMG educational programs are designed primarily as an educational tool for health care providers who wish to increase their understanding of the application of genomic technologies to patient care. The ACMG does not endorse or recommend the use of this educational program to make patient diagnoses, particularly by individuals not trained in medical genetics. Adherence to the information provided in these programs does not necessarily ensure a successful diagnostic outcome. The program should not be considered inclusive of all proper procedures and or exclusive of other procedures and that are reasonably directed at obtaining the same results. In determining the propriety of any specific procedure or, a healthcare provider should apply his or her own professional judgment to the specific clinical circumstances presented by the individual patient or specimen.
Questions regarding CE credit should be directed to education@acmg.net